Stay updated on Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Sign up to get notified when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Revision bumped from v3.3.3 to v3.3.4. No user-facing content changes observed on the Study Details page.
    Difference
    0.1%
    Check dated 2026-01-14T03:16:41.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Locations section updated to include California, Maryland, Massachusetts, Nevada, Pennsylvania, Tennessee, and Texas, and the revision note updated to v3.3.3 (replacing v3.3.2).
    Difference
    0.9%
    Check dated 2025-12-23T17:31:29.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The Publications section now notes that entries are automatically filled from PubMed and may not all relate to the study. The page revision indicates Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-11-24T21:19:09.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The page removed the notice about government funding and operating status. This does not affect the study details or participation information.
    Difference
    0.4%
    Check dated 2025-11-17T18:43:44.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    No significant additions or deletions were observed on the Study Details page for NCT03066258; the critical study information, eligibility criteria, locations, and timelines remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-03T13:45:06.000Z thumbnail image
  8. Check
    105 days ago
    Change Detected
    Summary
    Significant update: new operating-status notice and funding-related limitations are added, plus a version bump to v3.2.0; previous v3.1.0 deletion indicates a version upgrade.
    Difference
    4%
    Check dated 2025-10-06T02:15:37.000Z thumbnail image

Stay in the know with updates to Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety of RGX-314 Gene Therapy in Neovascular AMD Clinical Trial page.